An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole

Trial Profile

An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2013

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications Gastro-oesophageal reflux; Heartburn; Reflux oesophagitis
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 May 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 24 May 2012 Actual patients number is 107 as reported by ClinicalTrials.gov.
    • 24 May 2012 Actual initiation date (Aug 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top